Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Design, development, and optimization of in situ-forming implants for intra-articular delivery of celecoxib in osteoarthritis

  • Cunalema, Carmen
  • Kargin, Sena
  • Flores, Xcaret
  • Celis, Ana C.
  • Fraguas Sánchez, Ana Isabel
  • Fernández Carballido, Ana María
Osteoarthritis (OA) is a prevalent chronic joint disease characterized by pain, swelling, and physical disability. Its management includes the use of anti-inflammatory drugs, including intra-articular corticosteroids and oral NSAIDs such as COX-2 selective inhibitors like Celecoxib (CXB). The intra-articular administration of corticosteroids is highly effective. However, long-term corticosteroid use causes cartilage degradation, whereas oral CXB is associated with cardiovascular toxicity. The intra-articular CXB delivery may reduce systemic exposure, yet rapid joint clearance limits its utility. Therefore, this study aimed to design, develop, and optimize intraarticular in situ forming implants of CXB (CXB-ISFI) to provide controlled drug release over 6–8 weeks for the treatment of OA and overcome rapid joint elimination and enable sustained local drug exposure. The DoE approach based on a two-level factorial experimental design was used to optimize a CXB-ISFI formulation with a suitable release profile, evaluating the effect of solvent and polymer type, polymer concentration and CXB content. The type of solvent and the polymer concentration showed a significant influence on CXB release during the initial phase (%Q2). In contrast, the polymer type was a significant factor for the late phase (%Q60). All these factors had a significant impact on dissolution efficiency at 60 days (%DE60). The optimized formulation, prepared with 150 mg of PLGA and DMSO, at a polymer concentration of 50% and a CXB content of 20% showed a controlled drug release over 8 weeks with a minimized burst effect. It exhibited good injectability through a 21G needle and no signs of toxicity in the HET-CAM assay. These findings indicate its suitability for intra-articular administration and its potential use in the treatment of OA as an alternative to intra-articular corticosteroids.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Cannabidiol-loaded-injectable depot formulation for the treatment of triple-negative breast cancer: design, development, in-vitro and in-ovo evaluation of its anticancer activity

  • Lozza, Irene
  • Hurtado-Marcos, Carolina
  • Montejo-Rubio, Consuelo
  • Martín Sabroso, Cristina
  • Fraguas Sánchez, Ana Isabel
  • Torres Suárez, Ana Isabel
Triple-negative breast cancer (TNBC) is an invasive and difficult-to-treat carcinoma that represents 15–20 % of breast malignancies and is frequently diagnosed in younger women. Chemotherapy is the mainstay treatment approach. Cannabidiol (CBD), the main non-psychoactive cannabinoid, has shown a potential anticancer activity in TNBC, enhancing the effect of conventional antineoplastics. This research aims to develop in situ forming implants (ISFIs) as a long-acting depot formulation of CBD with potential application in TNBC. This formulation is intended to be administered in the tumor site during neoadjuvant chemotherapeutic regimens, allowing a controlled CBD release. ISFIs were elaborated with 100 mg of polycaprolactone (PCL) and 2.5 mg (2.5-CB-ISFI), 5 mg (5-CB-ISFI) or 10 mg (10-CB-ISFI) of CBD dissolved in 400 µL of NMP. All the formulations exhibited a controlled drug release for around two months. 10-CB-ISFI formulation with the highest CBD content and the most suitable CBD release profile was selected for biological studies. This formulation inhibited the proliferation and migration of MDA-MB-231 and 4T1 cells and exerted an antiangiogenic effect in ovo. Interestingly, the antiangiogenic activity of 10-CB-ISFI was higher compared with CBD in solution administered at the same concentration, showing vascular inhibition percentages of around 80 % and 60 %, respectively. Finally, this formulation reduced the growth of MDA-MB-231-derived tumors developed in the chorioallantoic membrane (CAM) model. The single administration of 10-CB-ISFI exhibited a similar antitumor efficacy to the daily administration of CBD in solution (≈60 % tumor growth inhibition). Therefore, the injectable depot formulation of CBD developed in this work showed a promising utility in TNBC treatment.